BAY 361677

Drug Profile

BAY 361677

Alternative Names: Interleukin-4 variant - Bayer

Latest Information Update: 06 Oct 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Interleukin 4 receptor agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; Multiple sclerosis

Most Recent Events

  • 06 Oct 2006 Discontinued - Phase-I for Multiple sclerosis in USA (unspecified route)
  • 06 Oct 2006 Discontinued - Preclinical for Acute lymphoblastic leukaemia in USA (unspecified route)
  • 15 Aug 2002 A clinical study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top